Symbols

TSHA

Taysha Gene·NASDAQ

--(--)

TSHA fundamentals

TSHA Q4 2025 Earnings

Taysha Gene (TSHA) released its earnings on Mar 19, 2026: revenue was 5.48M (YoY +171.17%), beat estimates; EPS was -0.08 (YoY -14.29%), beat estimates.

Revenue / YoY

5.48M

+171.17%

EPS / YoY

-0.08

-14.29%

Report date

Mar 19, 2026

TSHA Earnings Call Summary for Q4,2025

FDA Alignment & Clinical Progress: Received Breakthrough Therapy Designation and FDA alignment on pivotal trial designs, with REVEAL pivotal trial dosing underway and ASPIRE trial for younger patients approved.
Strong Safety Profile: No treatment-related serious adverse events in REVEAL Part A and pivotal trial, supporting intrathecal administration's safety.
Commercial Readiness: Appointed market access leader and raised $50M for 2027 inventory build, with cash runway to 2028.
Upcoming Milestones: 6-month pivotal trial data by end-2026 and 12-month Part A update in Q2 2026, positioning for potential BLA filing in 2027.

Earnings

EPS

Revenue

Revenue & Expenses

TSHA has released its 2025 Q4 earnings report, with revenue of 5.49M, reflecting a YoY change of 171.27%, and net profit of -27.85M, showing a YoY change of -48.26%. The Sankey diagram below clearly presents TSHA's revenue sources and cost distribution.

Key Indicators

Taysha Gene (TSHA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Taysha Gene (TSHA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Taysha Gene (TSHA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Taysha Gene (TSHA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown